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ABSTRACT
Objectives: To describe the clinical profile of Brazilian
patients with type 2 diabetes attending the public
healthcare system and identify factors associated with
poor glycaemic control.
Design: Cross-sectional study.
Setting: 14 centres in five regions of Brazil, including
primary care units and outpatient clinics of University
Hospitals.
Participants: Patients with type 2 diabetes attending
outpatient clinics of public healthcare system.
Main outcome measured: Glycated haemoglobin
(HbA1c), centrally measured by high-performance liquid
chromatography (National Glycohemoglobin
Standardization Program certified).
Results: A total of 5750 patients aged 61±10 years, with
11±8 years of diabetes duration (66% women, 56% non-
white, body mass index: 28.0±5.3 kg/m2) were analysed.
Mean HbA1c was 8.6±2.2%, and median HbA1c was
8.1% (6.9% to 9.9%). HbA1c <7% was observed in only
26% of patients. Mean HbA1c was higher (p < 0.01) in
the North (9.0±2.6%) and Northeast (8.9±2.4%) than in
the Midwest (8.1±2%), Southeast (8.4±2.1%) and South
regions (8.3±1.9%). Using the cut-off value of HbA1c
above the median, age (0.986 (0.983 to 0.989)), white
ethnicity (0.931 (0.883 to 0.981)) and being from
Midwest region (0.858 (0.745 to 0.989)) were protective
factors, while diabetes duration (1.015 (1.012 to 1.018)),
use of insulin (1.710 (1.624 to 1.802)) and living in the
Northeast region (1.197 (1.085 to 1.321)) were
associated with HbA1c >8%.
Conclusions: The majority of Brazilian patients
with type 2 diabetes attending the public healthcare
system had HbA1c levels above recommended targets.
The recognition of Northeast residents and non-white
patients as vulnerable populations should guide future
policies and actions to prevent and control diabetes.
INTRODUCTION
Brazil is among the 10 countries with the
highest prevalence of diabetes mellitus (DM)
in the world—about 7.6%.1 2 Diabetes is the
ﬁfth underlying cause of death in Brazil,
affecting 2.5% of the population.3
Preliminary results obtained by our group4
show that only 24% of Brazilian patients with
diabetes had an HbA1c level below the
recommended target (HbA1c <7%5), despite
the availability of free medical care through
the public healthcare system (Sistema Único
de Saúde-SUS).6 Medical assistance and spe-
ciﬁc drugs, including metformin, sulfonylur-
eas and insulin, are provided free of charge
across the country through primary care
units and speciﬁc drugstores. Considering
that poor diabetic control is associated with
increased mortality in diabetic populations,7
it is important to analyse the possible factors
associated with the high levels of HbA1c in
the population.
Therefore, the aim of this study was to
describe the clinical proﬁle of patients with
type 2 diabetes receiving public healthcare in
the ﬁve regions of Brazil and identify factors
associated with poor glycaemic control.
ARTICLE SUMMARY
Strengths and limitations of this study
▪ To the best of our knowledge, this is the largest
surveillance study to assess glycaemic control in
Brazil. We used a certified method to analyse gly-
cated haemoglobin.
▪ However, (1) surveillance was based on self-
reported answers, although medical records
were consulted when available. (2) Only patients
attended by the public health system were
included and (3) lastly, due to its cross-sectional
design, our study was able to identify associa-
tions between several factors and glycaemic
control, but was unable to pinpoint risk factors.
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PATIENTS
A cross-sectional study was conducted between February
2006 and April 2011 at SUS outpatient clinics with 7201
patients with types 1 and 2 diabetes from the North
(n=500; 7%), Northeast (n=2184; 30%), Midwest (n=461;
6%), Southeast (n=3382; 47%) and South (n=674; 9%)
regions of Brazil. The number of patients in each region
reﬂects the regional population density as reported in
the 2000 national census.8 A preliminary report describ-
ing the characteristics of this patient population, for all
regions except the North, has been published.4 Brieﬂy,
the current study was designed to obtain a representative
sample of adult patients with type 2 diabetes living in
urban areas of Brazil. A total of 14 centres, located in 12
cities belonging to the ﬁve regions of our country were
included. The included cities were the largest in their
respective region and nine of them ranked among the
most populous municipalities in Brazil. We also consid-
ered that the data would be more reliable if they were col-
lected from public healthcare centres that usually take
care of at least 300 patients with diabetes/month. All
patients provided written informed consent.
In the present study, we reported the results for 5750
patients with type 2 diabetes for whom HbA1c values
were available. Type 2 diabetes was deﬁned as diabetes
diagnosed after 30 years of age without insulin use in
the ﬁrst 5 years after the diagnosis. Patients were from
the North (n=312; 5%), Northeast (n=1906, 33%),
Midwest (n=348, 6%), Southeast (n=2642, 46%) and
South (n=542, 9%) regions.
Assessment of clinical characteristics
Information on clinical variables (age, gender, ethnicity,
DM duration, body weight, height, physical activity and
medications in use,) was obtained by a standardised
questionnaire. Ethnicity was self-reported as white or
non-white (black, mixed or other—including Asian and
Native Brazilians). Marital status was categorised as living
with or without a partner, and employment status as
working or not currently employed. Educational status
was classiﬁed as at least 8 years or less than 8 years of
formal education. DM treatment was classiﬁed as none,
diet alone, oral agents, oral agents plus insulin and
insulin alone. Frequency of self-blood glucose monitor-
ing (SBGM) and hypoglycaemic episodes in the previous
year were recorded. Body mass index (BMI) was calcu-
lated (weight/height2; kg/m2). Data were collected in
14 cities representing the ﬁve regions of Brazil: South
(Porto Alegre, Curitiba), Southeast (São Paulo, Cotia,
Campinas, Belo Horizonte, Rio de Janeiro), Midwest
(Brasilia, Taguatinga), Northeast (Fortaleza, Recife,
Salvador), North (Belém, Manaus).
HbA1c measurements
HbA1c was measured in a central laboratory by an
ion-exchange high-performance liquid chromatography
method (reference range 4.7–6%) certiﬁed by the
National Glycohemoglobin Standardization Program and
calibrated to the Diabetes Control and Complications
Trial standard.
Statistical analyses
The ﬁve regions were compared in terms of clinical vari-
ables and HbA1c results by one-way analysis of variance
(with Bonferroni post hoc test) and χ² tests. The charac-
teristics of patients were evaluated according to glucose
control (median HBA1c), region of origin and self-
reported ethnic background. Prevalence ratio (PR) and
95% CI were obtained by Poisson regression analyses to
determine the association of different factors with HbA1c
>8% (dependent variable). Adjustment was made taking
into account independent variables selected based on
their signiﬁcance on univariate analyses and/or bio-
logical relevance (age, diabetes duration, ethnicity, living
with partner, working status, insulin use, SBGM and geo-
graphic region).
Variables were expressed as mean±SD, number of
cases (%) and median (25–75 IQ intervals). HbA1c was
also described as median. Statistical analyses were
carried out using SSPS V.18.0. p Values less than 0.05
(two tailed) were considered signiﬁcant.
RESULTS
A total of 5750 patients with type 2 diabetes were
included and the main characteristics were: age of 61
±10 years, diabetes duration of 11±8 years and BMI 28.0
±5.3 kg/m2. Most patients were women (66%), non-white
(56%) and lived with a partner (59%). One-third (33%)
had completed 8 years of formal education, 20% were
employed and 37% were not physically active. Regarding
treatment, 1% did not follow any kind of treatment for
diabetes, 6% were on diet alone, 57% were taking oral
agents, 22% used oral agents and insulin and 13%
insulin alone. Mean HbA1c was 8.6±2.2% and median
was 8.1% (IQR 6.9–9.9%). HbA1c <7% was found in only
26% of the patients.
Since the majority of the included patients had a poor
glycaemic control we decided to compare the characteris-
tic of patients grouped according to median HbA1c (8%).
Table 1 describes clinical characteristics and PR (CI 95%)
of patients with HbA1c ≥8% and <8%. In unadjusted
model, patients with HbA1c ≥8% were younger, non-
whites, with longer DM duration, more sedentary, mainly
from North and Northeast regions and treated more fre-
quently with insulin than patients with HbA1c <8%. After
adjustment, DM duration (1.015 (1.012 to 1.018)), insulin
use (1.710 (1.624 to 1.802)) and being from Northeast
region (1.197 (1.085 to 1.321)) was associated with HbA1c
≥8%. On the other hand, age (0.986 (0.983 to 0.989)),
white ethnicity (0.931 (0.883 to 0.981)) and living in the
Midwest region (using the South region as reference;
(0.858 (0.745 to 0.989))) were protective factors. In order
to further explore the variables associated with HbA1c
≥8% we performed stratiﬁed analysis according to geo-
graphic region, ethnicity and insulin use. An online
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supplementary table shows unadjusted and adjusted ana-
lyses applying the same multivariate model using a cut-off
of HbA1c <7%. The differences between the groups of
patients with HbA1c <7% and ≥7% did not differ substan-
tially from the results using the cut-off of HbA1c <8%.
The characteristics of the patients stratiﬁed by region
are described in table 2. Mean HbA1c was higher
(p<0.01) in the North (9.0±2.6%) and Northeast (8.9
±2.4%) than in the Midwest (8.1±2%), Southeast (8.4
±2.1%) and South (8.3±1.9%) regions. Moreover, the
ﬁve regions differed in all other evaluated characteris-
tics. Patients living in the Northeast had the highest
prevalence of non-whites, the lowest BMI and the
highest frequency of employed individuals.
Characteristics of patients according to self-reported
ethnicity (white and non-white) are described in table 3.
Non-white patients had higher HbA1c values, lower BMI
and more years of formal education than white patients.
They were also younger, more often female and single.
Of the 5750 patients in this study, 35% (2021 patients)
used insulin. Of these, 33% (n=658) used insulin once
daily, 58% (n=1154) twice daily and 9% (n=189) three
times a day or more. Eighty-one per cent (n=1630) of
the insulin users performed SBGM, but only 421 (26%)
did it on a daily basis. Patients who performed more fre-
quently SBGM had lower values of HbA1c (at least once
daily: 9.3±2.1%) than those who did not measure capil-
lary glucose (9.7±2.3%; p=0.008).
CONCLUSIONS
In this study, most patients with type 2 diabetes attend-
ing the public healthcare system in Brazil had HbA1c
levels above the recommended target, that is, above 7%.
Being non-white and from the northeast, as well as the
longer diabetes duration, and insulin use were factors
associated with poor metabolic control, whereas age and
being from the Midwest were associated with HbA1c
<8% (median HbA1c level for this population). To the
best of our knowledge, this is the largest surveillance
study to assess glycaemic control in Brazil using a certi-
ﬁed method to measure HbA1c. We also may consider
that the present study included a representative sample
of patients with type 2 diabetes living in the urban areas
and attending the public healthcare system in Brazil.
In the current survey we chose to use the cut-off value
of HbA1c 8% to compare patients with different gly-
caemic control. The recommended target for HbA1c is
below 7%, but it has been recently recommended to
individualise the goal of HbA1c.5 Since only 26% of our
patients achieved this target, we adopted a more repre-
sentative cut-off value (median HbA1c value of our study
Table 1 Prevalence of patients’ characteristics according to HbA1c ≥8%
HbA1c <8% HbA1c ≥8%
PR (95% CI) p Value Adjusted PR (95% CI)* p ValueN=2791 N=2959
Age (years) 62±11 60±10 0.991 (0.989 to 0.993) 0.000 0.986 (0.983 to 0.989) 0.000
Diabetes duration (years) 9±8 12±8 1.018 (1.015 to 1.021) 0.000 1.015 (1.012 to 1.018) 0.000
BMI (kg/m2) 28.0±5.1 28. 0±5.4 0.999 (0.994 to 1.004) 0.640 – –
Females 1824 (65) 1972 (67) 0.972 (0.922 to 1.026) 0.304 – –
White 1339 (48) 1199 (40) 0.862 (0.818 to 0.907) 0.000 0.931 (0.883 to 0.981) 0.007
Living with a partner 1613 (58) 1762 (59) 1.035 (0.983 to 1.089) 0.189 1.006 (0.959 to 1.057) 0.796
≥8 years of formal education 933 (41) 967 (48) 0.987 (0.932 to 1.044) 0.646 – –
Active worker 527 (19) 609 (21) 0.949 (0.893 to 1.009) 0.094 1.053 (0.989 to 1.212) 0.109
Ever participate in a diabetes
education program†
318 (11) 387 (13) 0.929 (0.865 to 0.999) 0.047 – –
Diabetes treatment 0.000 – –
None 48 (2) 23 (1) 0.522 (0.346 to 0.786)
Diet only 285 (10) 58 (2) 1.302 (0.928 to 1.827)
Oral agents 1905 (69) 1390 (47) 2.300 (1.641 to 3.224)
Oral agents and insulin 318 (11) 930 (32) 2.176 (1.551 to 3.055)
Insulin alone 228 (8) 545 (18)
Insulin use 546 (20) 1475 (50) 1.834 (1.749 to 1.924) 0.000 1.710 (1.624 to 1.802) 0.000
SBGM 1838 (66) 2158 (73) 1.186 (1.118 to 1.1258) 0.000 1.061 (1.001 to 1.1.23) 0.045
Geographic region 0.000 0.000
North 135 (5) 177 (6) 1.225 (1.073 to 1.399) 1.137 (0.996 to 1.298)
Northeast 814 (29) 1092 (50) 1.212 (1.212 to 1.365) 1.197 (1.085 to 1.321)
Midwest 194 (7) 154 (5) 0.956 (0.842 to 1.109) 0.858 (0.745 to 0.989)
Southeast 1357 (49) 1285 (43) 1.050 (0.951 to 1.159) 0.959 (0.871 to 1.056)
South 291 (10) 251 (8)
*Poisson regression adjusted for: age, diabetes duration, ethnicity, living with partner, working status, insulin use, SBGM and geographic
region.
†Data not available for North region (not included in the adjusted analysis).
BMI, body mass index; PR, prevalence ratio; SBGM, self-blood glucose monitoring.
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Table 2 Characteristics of patients with type 2 diabetes according to the five geographic regions of Brazil
North Northeast Midwest Southeast South p Value
N 312 1906 348 2642 542 —
HbA1c (%) 9.0±2.6 8.9±2.4 8.1±2.0 8.4±2.1 8.3±1.9 <0.01*
Age (years) 58±10 61±11 60±11 61±10 62±10 <0.01†,‡
Diabetes duration (years) 10±8 10±8 11±8 11±9 11±9 0.029
BMI (kg/m2) 29.0±5.5 27.2±5.0 27.7±5.2 28.2±5.3 29.1±5.3 <0.01‡,§,¶
Females 193 (62) 1317 (69) 245 (70) 1726 (65) 315 (58) <0.01**
White 71 (23) 560 (29) 131 (38) 1311 (50) 465 (86) <0.01**
Living with a partner 199 (64) 1099 (58) 185 (53) 1537 (58) 355 (66) <0.01††
≥8 years of formal education 140 (45) 521 (27) 106 (30) 1011 (38) 122 (27) <0.01‡‡
Active worker 112 (36) 341 (18) 65 (19) 482 (18) 136 (25) <0.01§§
Sedentary 134 (43) 670 (35) 147 (43) 1005 (38) 168 (31) <0.01¶¶
Diabetes treatment
None 2 (1) 18 (1) 7 (2) 38 (1) 6 (1) <0.01**
Diet only 14 (5) 145 (8) 31 (9) 138 (5) 15 (3)
Oral agents 172 (59) 1172 (62) 180 (52) 1426 (54) 345 (64)
Oral agents and insulin 67 (23) 332 (17) 64 (18) 660 (25) 125 (23)
Insulin alone 37 (12) 239 (12) 66 (19) 380 (15) 51 (9)
Data are mean±SD or number of patients with the characteristic (%).
*North and Northeast versus Midwest, Southeast and South.
†North versus Northeast, Southeast and South.
‡Midwest and Southeast versus South.
§North versus Northeast and Center-West.
¶Northeast versus Southeast and South.
**Linear-by-linear association.
††Higher in North and South; lower in Midwest.
‡‡Higher in North; lower in Northeast and South.
§§Higher in North and South; lower in Northeast and Southeast.
¶¶Higher in North and Midwest; lower in Northeast and South.
BMI, body mass index.
Table 3 Demographic and clinical characteristics of patients with type 2 diabetes according to ethnicity
White Non-white
p ValueN=2538 N=3208
HbA1c (%) 8.3±2.1 8.8±2.3 <0.01
Age (years) 62±10 60±10 <0.01
Diabetes duration (years) 11±9 11±8 0.06
BMI (kg/m2) 28.2±5.2 27.8±5.3 0.003
Females—n (%) 1615 (64) 2178 (68) <0.01
Living with a partner—n (%) 1568 (62) 1805 (56) <0.01
At least 8 years of formal education—n (%) 803 (38) 1094 (41) 0.011
Active worker—n (%) 520 (21) 616 (19) 0.227
Sedentary—n (%) 904 (36) 1220 (38) 0.072
Diabetes treatment—n (%) 0.007
None 37 (2) 34 (1)
Diet only 151 (6) 192 (6)
Oral agents 1498 (59) 1794 (56)
Oral agents and insulin 533 (21) 714 (22)
Insulin alone 314 (12) 459 (15)
Geographic region—n (%) <0.01
North 71 (23) 241 (77)
Northeast 560 (29) 1344 (71)
Midwest 131 (38) 217 (62)
Southeast 1311 (50) 1329 (50)
South 465 (86) 77 (14)
Data are mean±SD, number of patients with the characteristic.
BMI, body mass index; HbA1c, glycated haemoglobin.
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population). Nevertheless, we also performed an analysis
using the cut-off of HbA1c <7% and the results did not
change.
Diabetes control varies in different countries. In the
USA, mean HbA1c among middle-aged adults was
approximately 7.3%.9 Patients with type 2 diabetes using
oral agents to treat diabetes in seven European countries
had similar glycaemic control (mean HbA1c 7.2%).10
However, in the EURIKA,11 a study performed in 12
European countries, only 36.7% of patients with type 2
diabetes achieved the goal of HbA1c <6.5%. In the
present study, mean HbA1c (8.6±2.2%) was much
higher than that observed in these countries, and only
26% of our patients had HbA1c below the 7% goal.
In our study, a broad range of HbA1c levels were also
observed across Brazilian regions. The poor glycaemic
control observed in the Northeast than the other
regions might be explained by a diverse ethnic and eco-
nomic background. Numerous studies show ethnic dis-
parities in HbA1c values; a meta-analysis has reported
that African-Americans had absolute HbA1c values
0.65% higher than non-Hispanic whites.12 According to
the Brazilian Geography and Statistics Institute, 23.6% of
the population in the North and 28.9% in Northeast are
white, versus 41.7% in the Midwest, 56.7% in the
Southeast and 78.5% in the South.13 In our study, the
difference in HbA1c between whites and non-whites was
about 0.5%. Regarding the role of economic status, per
capita income is almost twice as high in the South than
in the Northeast.14 In this sense, a European surveil-
lance of socioeconomic predictors of mortality has
demonstrated an association between low income15 and
higher mortality in men with type 2 diabetes.
Free, universal healthcare has been available to all
Brazilian citizens since 1988,6 including free access to
many drugs. Metformin, sulfonylureas and insulin are dis-
tributed in primary care units and drugstores around the
country. However, other medications used to treat dia-
betes are not covered. Also, SBGM devices are not freely
supplied. Therefore, although our Public Health System
may represent an advance in healthcare, it has not been
enough to reach glycaemic control targets in diabetes
care. Other measures are highly necessary, and should
include a structured diabetes education programme,16
public policies to improve adherence to diet and exer-
cise, and free access to SBGM, at least to all patients on
insulin.5
The present study has limitations. First, surveillance
was based on self-reported answers, although medical
records were consulted when available. Second, only
patients attending the public healthcare system were
evaluated and it is known that almost one-fourth of the
Brazilian population rely on private healthcare.17 Finally,
due to its cross-sectional design, our study was able to
identify associations between several factors and gly-
caemic control, but was unable to pinpoint risk factors.
It is also important to remember that reverse causality is
always possible in cross-sectional studies, and poor
glycaemic control in patients using insulin cannot be
attributed to insulin prescription per se. As insulin is
generally prescribed to patients with more severe dia-
betes, the health status of these patients may also
account for their poor glycaemic control. We may con-
sider that only patients with diabetes living in urban
areas could represent a potential limitation. However we
can speculate that patients from the rural areas of our
country, who attend primary care units less equipped
and with less trained healthcare personnel, may have
even poorer diabetes control.
In conclusion, Brazilian patients with type 2 diabetes
attending the public healthcare system have poor gly-
caemic control as demonstrated by HbA1c values far
above the recommended target. New strategies are
necessary to improve glycaemic control in this popula-
tion. Furthermore, the increased vulnerability of
Northeast residents and non-white patients to poor
metabolic control should be taken into account when
designing strategies to control diabetes.
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